Payment overview · 2025
General Payments
$616.52
33 reported records · 13 companies
Healthcare provider profile · identity verified
Tamara Erlikh, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · BRONX, NY · NPI 1518900471
Verified facts
What the public records show
CMS Open Payments records show Tamara Erlikh, M.D. received $616.52 in general payments during 2025 across 33 reported records.
Amgen Inc. accounted for 22.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Entresto, Kerendia, Otezla, Prolia.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Otezla by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Kerendia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Shingrix by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Entresto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 679 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $135.97 | 22.1% | 8 | 2025 |
| Intra-Sana Laboratories | Unresolved — no canonical attribution shown | $116.71 | 18.9% | 5 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $77.64 | 12.6% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $75.83 | 12.3% | 4 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $41.55 | 6.7% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $33.23 | 5.4% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $28.73 | 4.7% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $21.65 | 3.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $19.11 | 3.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.21 | 3.0% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $17.55 | 2.9% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.60 | 2.5% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $14.74 | 2.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $616.52 | 33 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| GLYCATE Normalized: glycate |
Drug | Intra-Sana Laboratories | $116.71 | 5 | 2025 |
Source payment records
|
|||||
| RELTONE 200 MG Normalized: reltone 200 mg |
Drug | Intra-Sana Laboratories | $116.71 | 5 | 2025 |
Source payment records
|
|||||
| RELTONE 400 MG Normalized: reltone 400 mg |
Drug | Intra-Sana Laboratories | $116.71 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $98.83 | 6 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $98.83 | 6 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $77.64 | 4 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $75.83 | 4 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $41.55 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $37.14 | 2 | 2025 |
Source payment records
|
|||||
| VOWST Normalized: vowst |
Biological | Aimmune Therapeutics, Inc. | $33.23 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $28.73 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $21.65 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $21.48 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $19.90 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $19.11 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $18.21 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $18.21 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $17.55 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $15.60 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $14.74 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 679 | exact normalized | Medicare Part D |
| ENTRESTO entresto |
2025 | Entresto | 2024 | 52 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| OTEZLA otezla |
2025 | Otezla | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 19 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
19 | 12 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
111 | 42 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
14 | 11 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
679 | 61 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1311 | 142 |
| Amlodipine Besylate | Amlodipine Besylate | 821 | 102 |
| Eliquis | Apixaban | 679 | 61 |
| Metoprolol Succinate | Metoprolol Succinate | 664 | 78 |
| Gabapentin | Gabapentin | 663 | 80 |
| Furosemide | Furosemide | 517 | 68 |
| Levothyroxine Sodium | Levothyroxine Sodium | 448 | 49 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 442 | 75 |
| Tamsulosin Hcl | Tamsulosin Hcl | 437 | 44 |
| Nifedipine Er | Nifedipine | 407 | 47 |
| Pantoprazole Sodium | Pantoprazole Sodium | 401 | 53 |
| Lisinopril | Lisinopril | 371 | 37 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 319 | 69 |
| Ezetimibe | Ezetimibe | 315 | 44 |
| Jardiance | Empagliflozin | 275 | 33 |
| Mirtazapine | Mirtazapine | 275 | 39 |
| Carvedilol | Carvedilol | 263 | 37 |
| Metformin Hcl | Metformin Hcl | 262 | 45 |
| Losartan Potassium | Losartan Potassium | 261 | 44 |
| Famotidine | Famotidine | 252 | 40 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 246 | 31 |
| Januvia | Sitagliptin Phosphate | 245 | 29 |
| Latanoprost | Latanoprost | 239 | 44 |
| Clopidogrel | Clopidogrel Bisulfate | 237 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 233 | 18 |
| Levetiracetam | Levetiracetam | 209 | 18 |
| Montelukast Sodium | Montelukast Sodium | 200 | 24 |
| Trulicity | Dulaglutide | 194 | 19 |
| Omeprazole | Omeprazole | 193 | 33 |
| Finasteride | Finasteride | 186 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 172 | 27 |
| Hydralazine Hcl | Hydralazine Hcl | 169 | 24 |
| Meclizine Hcl | Meclizine Hcl | 159 | 26 |
| Sevelamer Carbonate | Sevelamer Carbonate | 159 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 153 | suppressed |
| Memantine Hcl | Memantine Hcl | 152 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 143 | 30 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 139 | 13 |
| Allopurinol | Allopurinol | 132 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 126 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 123 | 28 |
| Simvastatin | Simvastatin | 118 | 23 |
| Torsemide | Torsemide | 116 | 12 |
| Alendronate Sodium | Alendronate Sodium | 111 | 16 |
| Lokelma | Sodium Zirconium Cyclosilicate | 111 | 42 |
| Donepezil Hcl | Donepezil Hcl | 109 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 106 | suppressed |
| Prednisone | Prednisone | 105 | 30 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 104 | 31 |
| Divalproex Sodium | Divalproex Sodium | 99 | suppressed |
| Tradjenta | Linagliptin | 99 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 93 | 22 |
| Ondansetron Hcl | Ondansetron Hcl | 92 | 42 |
| Lidocaine | Lidocaine | 87 | 21 |
| Admelog Solostar | Insulin Lispro | 86 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 83 | 14 |
| Linzess | Linaclotide | 81 | 14 |
| Risperidone | Risperidone | 81 | suppressed |
| Olanzapine | Olanzapine | 80 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 78 | 25 |
| Baclofen | Baclofen | 77 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 75 | suppressed |
| Xarelto | Rivaroxaban | 74 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 72 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 68 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 68 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 68 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 67 | suppressed |
| Haloperidol | Haloperidol | 67 | suppressed |
| Methimazole | Methimazole | 67 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 65 | 18 |
| Incruse Ellipta | Umeclidinium Bromide | 61 | 14 |
| Novolog Flexpen | Insulin Aspart | 61 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 61 | 24 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 60 | 15 |
| Spironolactone | Spironolactone | 59 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 57 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 55 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 55 | suppressed |
| Ibuprofen | Ibuprofen | 54 | 21 |
| Carbamazepine | Carbamazepine | 53 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 52 | suppressed |
| Entresto | Sacubitril/Valsartan | 52 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 52 | suppressed |
| Irbesartan | Irbesartan | 52 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 51 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 51 | 11 |
| Meloxicam | Meloxicam | 49 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 48 | 17 |
| Humalog Kwikpen U-100 | Insulin Lispro | 47 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 47 | suppressed |
| Ozempic | Semaglutide | 47 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 47 | suppressed |
| Azithromycin | Azithromycin | 46 | 36 |
| Ammonium Lactate | Ammonium Lactate | 45 | 22 |
| Methenamine Hippurate | Methenamine Hippurate | 42 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 42 | 30 |
| Benztropine Mesylate | Benztropine Mesylate | 41 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 41 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 41 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 41 | suppressed |
| Donepezil Hcl Odt | Donepezil Hcl | 40 | suppressed |
| Lactulose | Lactulose | 40 | suppressed |
| Mounjaro | Tirzepatide | 40 | suppressed |
| Rivastigmine | Rivastigmine | 40 | suppressed |
| Primidone | Primidone | 39 | suppressed |
| Clotrimazole | Clotrimazole | 38 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 38 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 38 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 38 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 37 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 37 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 36 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 36 | suppressed |
| Repatha Syringe | Evolocumab | 35 | suppressed |
| Colchicine | Colchicine | 34 | suppressed |
| Febuxostat | Febuxostat | 34 | suppressed |
| Levofloxacin | Levofloxacin | 34 | 22 |
| Sodium Chloride | 0.9 % Sodium Chloride | 33 | 21 |
| Ceftriaxone | Ceftriaxone Sodium | 32 | 25 |
| Roflumilast | Roflumilast | 32 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 31 | suppressed |
| Lovastatin | Lovastatin | 31 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 29 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 29 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 29 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 29 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 19 |
| Doxycycline Hyclate | Doxycycline Hyclate | 28 | 21 |
| Risedronate Sodium | Risedronate Sodium | 28 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 27 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 27 | suppressed |
| Entecavir | Entecavir | 27 | suppressed |
| Glipizide | Glipizide | 27 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 27 | suppressed |
| Otezla | Apremilast | 27 | suppressed |
| Repatha Sureclick | Evolocumab | 27 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 27 | suppressed |
| Atenolol | Atenolol | 26 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 26 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 26 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 26 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 26 | suppressed |
| Vascepa | Icosapent Ethyl | 26 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 25 | 16 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 25 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 25 | 11 |
| Metoclopramide Hcl | Metoclopramide Hcl | 25 | suppressed |
| Naproxen | Naproxen | 25 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 25 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 25 | suppressed |
| Calcium Acetate | Calcium Acetate | 24 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 24 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Timolol Maleate | Timolol Maleate | 24 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 24 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 24 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 23 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 23 | 16 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 22 | 12 |
| Enulose | Lactulose | 22 | suppressed |
| Lumigan | Bimatoprost | 22 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 22 | suppressed |
| Calcitriol | Calcitriol | 21 | suppressed |
| Lamotrigine | Lamotrigine | 21 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 20 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 20 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 20 | suppressed |
| Valsartan | Valsartan | 20 | suppressed |
| Alprazolam | Alprazolam | 19 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 19 | suppressed |
| Pregabalin | Pregabalin | 19 | suppressed |
| Prolia | Denosumab | 19 | 12 |
| Dorzolamide Hcl | Dorzolamide Hcl | 18 | suppressed |
| Nitroglycerin | Nitroglycerin | 18 | suppressed |
| Potassium Chloride | Potassium Chloride | 18 | 12 |
| Tivicay | Dolutegravir Sodium | 18 | suppressed |
| Abiraterone Acetate | Abiraterone Acetate | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 15 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 14 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 14 | suppressed |
| Glimepiride | Glimepiride | 14 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 14 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 14 | 11 |
| Anastrozole | Anastrozole | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Bystolic | Nebivolol Hcl | 13 | suppressed |
| Clonazepam | Clonazepam | 13 | suppressed |
| Invokana | Canagliflozin | 13 | suppressed |
| Moxifloxacin | Moxifloxacin Hcl | 13 | 11 |
| Mupirocin | Mupirocin | 13 | suppressed |
| Paxlovid (Eua) | Nirmatrelvir/Ritonavir | 13 | 13 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Carbidopa-Levodopa-Entacapone | Carbidopa/Levodopa/Entacapone | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Lacosamide | Lacosamide | 12 | suppressed |
| Levetiracetam Er | Levetiracetam | 12 | suppressed |
| Metolazone | Metolazone | 12 | suppressed |
| Nateglinide | Nateglinide | 12 | suppressed |
| Pioglitazone-Metformin | Pioglitazone Hcl/Metformin Hcl | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Complera | Emtricita/Rilpivirine/Tenof Df | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Kerendia | Finerenone | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 11 | suppressed |
| Rhopressa | Netarsudil Mesylate | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $616.52 · 33 records | Amgen Inc. | AIRSUPRA, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, ENTRESTO, EVENITY, GLYCATE, Kerendia, LEQVIO, NEXLETOL, NURTEC ODT, OTEZLA, PROLIA, RELTONE 200 MG, RELTONE 400 MG, REPATHA, REXULTI, TRELEGY ELLIPTA, VOWST, Veozah | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error